Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Pelthos Therapeutics ( (PTHS) ) just unveiled an update.
On April 6, 2026, Pelthos Therapeutics’ board appointed John M. Gay as Chief Financial Officer, treasurer and secretary, with the changes becoming effective April 10, 2026, and concurrently terminated former CFO Francis Knuettel II effective that same date, citing no disagreements over company operations. Gay, a veteran finance executive with more than 25 years of public company and accounting experience, joined Pelthos in 2025 as Senior Vice President of Finance & Accounting and will receive a $425,000 base salary plus performance-based bonus under a new employment agreement, underscoring the company’s effort to strengthen its financial leadership as it builds on recent capital raises and commercial momentum following its merger with Channel Therapeutics.
Pelthos announced that Knuettel’s treasury and secretary responsibilities transitioned to Gay on April 10, 2026, and indicated it expects to enter into a separation agreement with Knuettel pursuant to his existing contract, with material terms to be disclosed later if required. The leadership transition, formalized in an April 10, 2026 press release, comes as Pelthos seeks to sustain growth around its portfolio of dermatology-focused infectious disease therapies and signals a continuity-focused handover from a launch-phase CFO to a long-tenured finance leader integral to establishing the company.
The most recent analyst rating on (PTHS) stock is a Hold with a $22.50 price target. To see the full list of analyst forecasts on Pelthos Therapeutics stock, see the PTHS Stock Forecast page.
Spark’s Take on PTHS Stock
According to Spark, TipRanks’ AI Analyst, PTHS is a Neutral.
The score is held back mainly by weak current financials (large losses and ongoing cash burn) and a bearish technical backdrop (trading below major moving averages with negative MACD). Partially offsetting these risks, the latest earnings call points to strong early product traction and a clear path objective toward cash-flow breakeven, though execution and net-pricing (GTN) remain key uncertainties.
To see Spark’s full report on PTHS stock, click here.
More about Pelthos Therapeutics
Pelthos Therapeutics Inc. is a commercial-stage biopharmaceutical company focused on differentiated cutaneous infectious disease products addressing unmet patient needs. Its portfolio includes lead product ZELSUVMI topical gel for at-home treatment of Molluscum contagiosum, as well as Xepi Cream for impetigo and Xeglyze for head lice, targeting dermatology-related infectious conditions.
Average Trading Volume: 8,461
Technical Sentiment Signal: Hold
Current Market Cap: $75.77M
See more data about PTHS stock on TipRanks’ Stock Analysis page.